Andrew McGarry, MD
Vice President, Clinical Development, Clintrex

Andrew McGarry, MD obtained a neuroscience degree at the University of Rochester, is a graduate of the University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School and completed neurological training at the University of Rochester Medical Center, including a fellowship in Experimental Therapeutics and Movement Disorders.

At Clintrex he oversees the Clinical Development Division. Dr. McGarry has extensive experience analyzing and interpreting preclinical and clinical data, designing Phase 1, Phase 2, and Phase 3 clinical trials, oversight of study enrollment authorization, safety oversight for numerous studies including as Safety Monitoring Committee Chair, anomalous data review, and ongoing partnership with a variety of client personnel (preclinical, statistical, clinical, regulatory) to optimize the overall development plan.

He is also currently an Associate Professor of Neurology at Cooper University Healthcare at Rowan University, where he helps oversee the movement disorder clinic and treats a variety of neurodegenerative diseases. Dr. McGarry is a member of the Huntington’s and Parkinson’s Study Groups and has interest in genetic modifiers and metabolomics in Huntington’s Disease, non-motor features of Parkinson’s Disease, and rational repurposing of existing medications for unmet needs in movement disorders. He has served as site investigator or co-investigator for numerous clinical studies, particularly in Huntington’s and Parkinson’s Disease, and has developed and initiated several investigator-initiated clinical studies. His experience also includes leadership and authorship for numerous manuscripts and book chapters over the last 15 years in neurodegenerative diseases.

.  .  .